有偏差的受体信号传递和结构上不同的甲基受体2激动剂的细胞内贩运概况
Cheng Peng1, Elizabeth A Vecchio1, Anh T N Nguyen1
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
British journal of pharmacology
|August 18, 2024
概括
这项研究揭示了FPR2激动剂的独特信号特征,区分了像ACT-389949这样的促溶解疗法与BMS-986235和化合物43等心脏保护剂的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
- 药物发现 药物发现 药物发现
背景情况:
- 越来越多的人对甲基受体2 (FPR2) 激动剂作为促进溶解的治疗方法越来越感兴趣.
- 目前,ACT-389949和BMS-986235正在进行I期临床试验.
- 激活FPR2产生了多种下游效应,对ACT-389949 (心肌疏松症) 和BMS-986235/化合物43 (心脏保护) 进行了明显的临床前观察.
研究的目的:
- 描述FPR2激动剂之间的联体受体参与的差异.
- 调查下游信号和贩运偏见的个人资料.
- 了解结构相互作用如何影响功能结果.
主要方法:
- 利用HEK293A细胞来评估G蛋白解离,β-逮捕素招募,受体贩运和第二信使信号传递.
- 采用操作模型进行偏差分析,使用WKYMVm作为参考连接体.
- 执行了FPR2连接体的分子对接到FPR2的活性冷EM结构 (PDBID: 7T6S).
主要成果:
- WKYMVm 和 ACT-389949 显示了类似的偏差配置文件.
- BMS-986235和化合物43显著偏向于cAMP抑制和pERK1/2激活,远离β-逮捕素的招募和贩运.
- 分子对接在FPR2内确定了WKYMVm/ACT-389949与BMS-986235/化合物43之间的显著氨基酸相互作用.
结论:
- 在体外表征突出了WKYMVm/ACT-389949和BMS-986235/化合物43之间的差异信号和蛋白质合配置文件.
- 观察到的差异可能归因于联体受体相互作用的变化.
- 这些发现为设计基于FPR2的药物疗法提供了关键的见解,具有所需的偏差配置文件.
相关概念视频
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Amplifying Signals via Second Messengers
6.8K
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
6.8K
Transducer Mechanism: G Protein–Coupled Receptors
1.9K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.9K
Assembly of Signaling Complexes
5.7K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.7K
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


